论文部分内容阅读
非霍奇金淋巴瘤(NHL)是临床常见的造血系统恶性肿瘤,是威胁人类生命的10大恶性肿瘤之一。大多数NHL起源于B淋巴细胞,95%以上的B细胞NHL表达CD20抗原。NHL对标准的治疗,包括放疗和化疗敏感,有效率高,但复发率也高。除了传统的抑制细胞生长的药物外,单克隆抗体的出现从本质上影响了人们对于非霍其金淋巴瘤(NHL)治疗的观念。美罗华是基于CD20抗原的单克隆抗体,现已广泛用于NHL的治疗,临床试验结果表明美罗华在滤泡性淋巴瘤、复发的B细胞NHL的解救治疗及维持治疗中具有重要的作用,与CHOP方案联合可以提高大细胞性淋巴瘤的治愈率。目前的研究热点在于将美罗华与化学免疫疗法联合起来,寻求剂量的最优化,以及新的治疗靶点,为临床的应用提供理论依据。
Non-Hodgkin’s lymphoma (NHL) is a common clinical hematopoietic malignant tumor, which is one of the 10 malignant tumors that threaten human life. Most NHLs originate in B lymphocytes, and over 95% of B-cell NHLs express CD20 antigens. NHL is more effective than standard treatment, including radiotherapy and chemotherapy, but has a high recurrence rate. In addition to the traditional drugs that inhibit cell growth, the appearance of monoclonal antibodies essentially affects the notion of non-Hodgkin lymphoma (NHL) treatment. Rituximab, a monoclonal antibody based on the CD20 antigen, is now widely used in the treatment of NHL. Clinical trials have shown that rituximab has an important role in the rescue and maintenance of follicular lymphoma and recurrent B cell NHL, Combination of programs can improve the cure rate of large cell lymphoma. The current research hotspot is to combine rituximab with chemical immunotherapy to seek optimal dose and new therapeutic target, which can provide the theoretical basis for clinical application.